The use of oxygen for the management of patients with acute breathlessness, irrespective of cause, is well established in medical practice. The perception of benefit, even in the absence of measurement of oxygenation, and concerns over adverse outcomes from severe hypoxaemia have driven the use of high-concentration oxygen therapy over many years with little regard to possible harmful effects. While there have been many advocates for the cautious use of oxygen in chronic obstructive pulmonary disease (COPD) as a result of its propensity to promote hypercarbia, liberal use in asthma appears universal. This approach pervades student teaching through medical texts, even when there is significant respiratory input into the publication 1 and extends to recent evidence-based guidelines on both asthma management and oxygen usage. The recently published British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines 2 recommend administration of oxygen for acute exacerbations of asthma, stating 'Many patients with acute severe asthma are hypoxaemic. Supplementary oxygen should be given urgently to hypoxaemic patients, using a face mask, Venturi mask or nasal cannulae with flow rates adjusted as necessary to maintain SpO 2 of 94e98%', advice that is allocated a moderate to low level of evidence. Furthermore, they emphasise the use of oxygen therapy even in the absence of information on oxygenation, recommending that the 'Lack of pulse oximetry should not prevent the use of oxygen'. Use of oxygen according to these recommendations is likely to result in a high fractional inspired oxygen, as 'In hospital, ambulance and primary care, nebulised b 2 agonist bronchodilators should preferably be driven by oxygen', noting 'A flow rate of 6 l/min is required to drive most nebulisers'. The recently published BTS guidelines on emergency oxygen use are more circumspect on use without measurement of oxygenation, 3 stating that there is no benefit from oxygen administration in non-hypoxic patients and emphasising that administration should be based on, and monitored by, objective measures.
The relationship between oxygen concentrations and airway diseases, particularly the impact on ventilatory responses, has been of interest for many years. As early as 1979, investigations were being carried out on the impact of hyperoxia in asthma, by measuring specific airway conductance during exerciseinduced bronchoconstriction and comparing patients with asthma who had bilateral carotid body resection with those having intact carotid bodies. Oxygen breathing during exercise markedly attenuated the post-exercise bronchospasm in patients with asthma who had intact carotid bodies, but had no significant effect in those without carotid bodies, unrelated to changes in end-tidal partial pressure of carbon dioxide. The authors concluded that oxygen attenuates exercise-induced bronchospasm in patients with asthma through its action on the carotid bodies. 4 Further reassurance on the safety of oxygen in asthma came in 1991, when bronchial reactivity to methacholine under normoxic and hyperoxic conditions was studied in a double-blind study involving nine patients with asthma. The provocative concentrations that caused a 20% fall in FEV 1 while breathing 21% and 100% oxygen were 0.18 mg/ml (range 0.06e5.73) and 0.25 mg/ml (range 0.07e8.49), respectively. These were not significantly different, allowing the investigators to conclude that 100% oxygen does not affect bronchial reactivity in asthma. 5 These studies seem to have been accepted as evidence that hyperoxia did not have an impact on asthma, yet a number of cases were reported in the literature suggesting that there may be cause for concern over oxygen use in asthma under some circumstances. Although these reports did not appear to alarm the medical fraternity, the broader asthma community seemed more concerned about hypercarbia in asthma. Internet postings noted 'A study was done in 1963 and written up in the New England Journal of Medicine [a very prestigious medical journal], where people were forced to breathe as deeply as they could for 15 minutes. After 15 minutes of deep breathing the level of oxygen had DROPPED greatly in the blood, and the CO 2 level had increased. So always rememberdyour lungs are a gas mixing chamber. They work best when you have the right mix of gases in themdjust like the carburettor of a car'. 6 Yet some medical practitioners did question the role of oxygen in cases of acute severe asthma, particularly those presenting in primary care. 7 They reported that a systematic review was not feasible as there had never been a randomised controlled trial of oxygen use in acute severe asthma, so they opted to present a narrative literature review. They went on to state that in acute severe asthma, nebulisation of b 2 agonists without oxygen can cause or worsen hypoxaemia and hypothesised that the continuing trickle of deaths from asthma in Britain is a result of hypoxaemia caused by air-driven nebulisers. They rationalised that the use of oxygen before, during and after nebulised b 2 agonist therapy in primary care and in the community was rational and could save lives, urging the BTS to review this issue when it updated its guidelines.
It was not until 2003 that the first controlled trial to investigate the effects of hyperoxia in patients with acute severe asthma was reported. 8 Seventy-four patients were randomised to receive 28% or 100% oxygen for 20 min. The administration of 100% oxygen significantly increased arterial carbon dioxide pressure (PaCO 2 ) compared with 28% oxygen, especially in those with PaCO 2 greater than 40 mm Hg before oxygen treatment. Supporting these observations, in this issue of the journal, Perrin et al report on findings that provide high-level evidence based on which recommendations have been made for oxygen administration in acute asthma. They report a randomised study comparing the effect of highconcentration oxygen delivered at 8 l/min via a face mask with oxygen titrated to achieve oxygen saturations of 93e95% in acute exacerbations of asthma presenting to an emergency department. Transcutaneous CO 2 pressure (PtCO 2 ) was used to measure the effect of the interventions, with the proportion of patients having a rise in PtCO 2 $4 mm Hg at 60 min being significantly greater in the high concentration oxygen group when compared with the titrated group. The investigators concluded that high-concentration oxygen therapy causes a clinically significant increase in PtCO 2 and they recommended the use of a titrated oxygen regime in the treatment of severe asthma. These results mirror those of a similar study performed recently in patients with COPD. 9 In this randomised, controlled, prehospital study, participants allocated to titrated oxygen therapy were significantly less likely to have respiratory acidosis (mean difference in pH 0.12; SE 0.05; p¼0.01; n¼38) or hypercapnoea (mean difference in PaCO 2 À33.6 mm Hg; SE 16.3; p¼0.02; n¼39) than patients receiving high-concentration oxygen. Treatment with titrated oxygen was also associated with a 58% reduction in mortality, the primary outcome in this study.
As asthma and COPD are prevalent diseases in the Western world, and acute exacerbations of either are associated with an increased risk of death, it is beholden to health professionals to ensure that they do not contribute to this outcome. We now have strong evidence to support the BTS guidelines on emergency oxygen use, which recommend that it be approached in the same way as any other drug, recognising that adverse outcomes may eventuate from either inappropriately low or high concentrations. Should the guidelines be revised in the light of this new evidence to better align recommendations with the philosophy of keeping arterial oxygen saturations 'within the target saturation range' that aim to 'achieve normal or near-normal oxygen saturation' and move away from any suggestion that high-concentration oxygen should be administered in the absence of objective evidence of a physiological need? With the advent of lowcost portable oxygen saturation monitors, surely it is time we followed the guideline exhortations to measure the fifth vital sign, as in the words of Willy Wonka 'it's the only way if you want it just right'.
Who will benefit from tracheostomy ventilation in motor neuron disease?
John M Shneerson
The decision when to recommend tracheostomy ventilation in motor neuron disease (amyotrophic lateral sclerosis) has always been difficult. At one extreme is the view that when spontaneous ventilation or non-invasive ventilation is inadequate, a tracheostomy will save the patient's life and lead to prolonged survival. This view has been more widely held in the USA than elsewhere. In the UK, a common position is the opposite, with a nihilistic attitude towards invasive respiratory treatment. The rationale behind this is that it is too intrusive, both for the patient and for the family and carers, and that once a tracheostomy is needed, palliative care is more appropriate.
Not surprisingly, there has been a wide geographical variation in the proportion of patients who proceed to a tracheostomy, and the review by Sancho et al 1 is timely. The authors describe a 9-year experience in a specialist respiratory care unit where the issues surrounding tracheostomy ventilation were openly discussed with each patient who might benefit from it. Out of 76 subjects 38 refused. Unfortunately, no further data are provided about these patients to compare their outcomes in terms of quality of life with the 38 who underwent a tracheostomy but their mean survival was only 0.83 months.
Interestingly, over half of those who underwent a tracheostomy did so during an acute severe chest infection in which non-invasive ventilation was either ineffective or not indicated. These patients were transferred from endotracheal intubation to tracheostomy ventilation. The indications were otherwise untreatable ventilatory failure or the need for access to tracheobronchial secretions during and after the infection. The mean survival after tracheostomy was 10.76 months, which was similar to the mean survival when tracheostomy was carried out electively.
As has also been reported in a recent study, 2 some of these patients eventually did not require continuous ventilatory support, but there is no mention of whether any could be weaned onto noninvasive ventilation once they recovered from their acute illness. Another report, however, suggests that almost half of those who undergo tracheostomy ventilation in this situation can eventually be weaned onto non-invasive support. 3 Their survival is as good as those who still require tracheostomy ventilation but they are more likely to be able to return home. 3 These encouraging findings suggest that there is a need for a re-appraisal of the management of severe chest infections in motor neuron disease. A much more active approach needs to be taken by intensivists, neurologists and respiratory physicians involved in their care than has been the standard practice in the past.
The indications for elective tracheostomy ventilation were either an inability to provide adequate ventilatory support 
